Published in Brain Res on September 23, 1982
The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A (1999) 1.41
Prescription opioid analgesics rapidly change the human brain. Pain (2011) 1.34
Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A (2011) 1.29
Opioid modulation of non-cholinergic neural bronchoconstriction in guinea-pig in vivo. Br J Pharmacol (1988) 1.27
Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys. Brain Res (2003) 1.01
Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys. J Pharmacol Exp Ther (2003) 0.94
Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex. Br J Pharmacol (2006) 0.91
Characterization of mu, kappa, and delta opioid binding in amphibian whole brain tissue homogenates. J Pharmacol Exp Ther (2002) 0.90
Kinetic modeling of (11)C-LY2795050, a novel antagonist radiotracer for PET imaging of the kappa opioid receptor in humans. J Cereb Blood Flow Metab (2014) 0.89
Evaluation of the kappa-opioid receptor-selective tracer [(11)C]GR103545 in awake rhesus macaques. Eur J Nucl Med Mol Imaging (2010) 0.88
Morphine modulation of pain processing in medial and lateral pain pathways. Mol Pain (2009) 0.88
Hypothalamic regulation of the cardiovascular and respiratory systems: role of specific opiate receptors. Br J Pharmacol (1983) 0.86
Biomarkers of epileptogenesis: psychiatric comorbidities (?). Neurotherapeutics (2014) 0.85
Interaction between family history of alcoholism and Locus of Control in the opioid regulation of impulsive responding under the influence of alcohol. Alcohol Clin Exp Res (2011) 0.84
μ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief. Psychopharmacology (Berl) (2012) 0.82
The response to rapid infusion of fentanyl in the human brain measured using pulsed arterial spin labelling. MAGMA (2011) 0.81
Evaluation of the agonist PET radioligand [¹¹C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242. Neuroimage (2014) 0.80
Association of frontal gray matter volume and cerebral perfusion in heroin addiction: a multimodal neuroimaging study. Front Psychiatry (2013) 0.79
The neuroanatomical delineation of agentic and affiliative extraversion. Cogn Affect Behav Neurosci (2015) 0.78
Pain and opiate receptors: considerations for the design of positron emission tomography studies. Anesth Prog (1991) 0.76
Investigation of cross-species translatability of pharmacological MRI in awake nonhuman primate - a buprenorphine challenge study. PLoS One (2014) 0.76
Central non-opioid physiological and pathophysiological effects of dynorphin A and related peptides. J Psychiatry Neurosci (1992) 0.76
One Month of Oral Morphine Decreases Gray Matter Volume in the Right Amygdala of Individuals with Low Back Pain: Confirmation of Previously Reported Magnetic Resonance Imaging Results. Pain Med (2015) 0.75
Psychotomimesis mediated by kappa opiate receptors. Science (1986) 3.60
A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res (2010) 3.15
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A (1992) 3.02
Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection. Infection (1993) 2.89
Fulminant liver failure in association with the emetic toxin of Bacillus cereus. N Engl J Med (1997) 2.76
Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A (1989) 2.51
Analgesic effect of intraarticular morphine after arthroscopic knee surgery. N Engl J Med (1991) 2.29
Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology (Berl) (1985) 2.16
Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther (1993) 2.01
Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res (2010) 1.99
Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med (1998) 1.93
Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther (1989) 1.89
Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci U S A (1990) 1.79
The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem (1990) 1.71
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
[Distribution of senile changes in the brain. The part of the limbic system in Alzheimer's disase and senile dementia]. Arch Psychiatr Nervenkr (1970) (1968) 1.61
Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds. Pharmacol Biochem Behav (1988) 1.60
On the central sites for the antinociceptive action of morphine and fentanyl. Neuropharmacology (1970) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia (1973) 1.46
Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin. J Neurosci (1990) 1.41
The response of Crohn's strictures to endoscopic balloon dilation. Aliment Pharmacol Ther (2009) 1.41
Legionella infection of the colon presenting as acute attack of ulcerative colitis. Gastroenterology (1989) 1.40
The Diet, Obesity and Genes (Diogenes) Dietary Study in eight European countries - a comprehensive design for long-term intervention. Obes Rev (2009) 1.40
Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest (1993) 1.35
Microelectrophoretic studies concerning the spread of glutamic acid and GABA in brain tissue. Exp Brain Res (1969) 1.32
Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience (1993) 1.29
Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond. Clin Immunol (2000) 1.25
Niemann-Pick disease type C: case report with ultrastructural findings. Neuropadiatrie (1973) 1.24
New isoniazid/ethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis strains. Lancet (1995) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. Psychopharmacology (Berl) (1989) 1.23
Aspects of opiate dependence in the myenteric plexus of the guinea-pig. Life Sci (1976) 1.23
Report from the killer immunoglobulin-like receptor (KIR) anthropology component of the 15th International Histocompatibility Workshop: worldwide variation in the KIR loci and further evidence for the co-evolution of KIR and HLA. Tissue Antigens (2010) 1.23
Differential effects of mu and kappa opioid systems on motivational processes. NIDA Res Monogr (1986) 1.23
In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol (1981) 1.21
Preference conditioning produced by opioid active and inactive isomers of levorphanol and morphine in rat. Life Sci (1986) 1.20
Quantitative study on dendrites and dendritic spines in Alzheimer's disease and senile dementia. Adv Neurol (1975) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J Pharmacol Exp Ther (1993) 1.18
Binding characteristics of a monoclonal beta-endorphin antibody recognizing the N-terminus of opioid peptides. J Neurochem (1983) 1.17
Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists. Brain Res (1987) 1.16
Electrically stimulated release of opiate-like material from the myenteric plexus of the guinea pig ileum. Eur J Pharmacol (1977) 1.16
Insulin-like growth factor II (IGF II) in human brain: regional distribution of IGF II and of higher molecular mass forms. Proc Natl Acad Sci U S A (1985) 1.16
AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter in mesangial cells. J Am Soc Nephrol (2000) 1.15
Monoclonal antibody to the message sequence Tyr-Gly-Gly-Phe of opioid peptides exhibits the specificity requirements of mammalian opioid receptors. Proc Natl Acad Sci U S A (1983) 1.14
Persistence of Borrelia burgdorferi and histopathological alterations in experimentally infected animals. A comparison with histopathological findings in human Lyme disease. Infection (1991) 1.13
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Electrophoretic release of tritium-labelled glutamic acid from micropipettes in vitro. Brain Res (1969) 1.10
Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. Mol Pharmacol (1990) 1.10
Selective receptors for beta-endorphin on the rat vas deferens. Life Sci (1979) 1.09
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett (2011) 1.08
Search for stopped Gluinos in pp collisions at square root s=7 TeV. Phys Rev Lett (2011) 1.07
Gene expression and localization of opioid peptides in immune cells of inflamed tissue: functional role in antinociception. Neuroscience (1992) 1.07
Calcium reverses the inhibitory action of morphine on neuroeffector transmission in the mouse vas deferens. Brain Res (1980) 1.07
[A cliniconeurophathological study of the "Lewy body disease"]. Seishin Shinkeigaku Zasshi (1980) 1.06
Pharmacologically induced alterations of cortical and subcortical evoked potentials compared with physiological changes during the awake-sleep cycle in cats. Electroencephalogr Clin Neurophysiol (1967) 1.06
Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines. Eur J Pharmacol (1993) 1.05
Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry (1976) 1.05
Measurement of the Υ1S, Υ2S, and Υ3S polarizations in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2013) 1.05
Analysis of mitochondrial targeting sequence and coding region polymorphisms of the manganese superoxide dismutase gene in German Parkinson disease patients. Biochem Biophys Res Commun (1999) 1.04
Possible antidepressive effects of opioids: action of buprenorphine. Ann N Y Acad Sci (1982) 1.04
Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther (1982) 1.04
Studies on the central antinociceptive action of cholinomimetic agents. Int J Neuropharmacol (1969) 1.04
New isoforms of multifunctional calcium/calmodulin-dependent protein kinase II. FEBS Lett (1993) 1.03
Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. Neurogenetics (1997) 1.02
Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol (2000) 1.01
Spine distribution along the apical dendrites of the pyramidal neurons in Down's syndrome. A quantitative Golgi study. Acta Neuropathol (1980) 1.01
Antinociceptive effects of mu- and kappa-agonists in inflammation are enhanced by a peripheral opioid receptor-specific mechanism. Eur J Pharmacol (1988) 1.01
Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action. J Pharmacol Exp Ther (1989) 1.01
Characteristics of a monoclonal beta-endorphin antibody recognizing the N-terminus of opioid peptides. Life Sci (1983) 1.01
[Measurement of gastric transepithelial potential difference. Effect of provocative agents (aspirin, alcohol) and gastric dressings]. Gastroenterol Clin Biol (1985) 1.00
Effect of low and high fat meals on lower esophageal sphincter motility and gastroesophageal reflux in healthy subjects. Am J Gastroenterol (1999) 1.00
Measurement of the polarization of W bosons with large transverse momenta in W + jets events at the LHC. Phys Rev Lett (2011) 0.99
Mixed opioid/nonopioid effects of dynorphin and dynorphin related peptides after their intrathecal injection in rats. Neuropeptides (1983) 0.99
Highly specific opiate receptors for dynorphin-(1-13) in the mouse vas deferens. Eur J Pharmacol (1980) 0.99
Pharmacokinetics of fentanyl in man and the rabbit. Eur J Clin Pharmacol (1972) 0.99
Dynorphin-related immunoreactive peptides in rat brain and pituitary. Neurosci Lett (1980) 0.99
Aneurysms and vacuolar degeneration of cerebral arteries in late-onset acid maltase deficiency. J Neurol Sci (1990) 0.99
Microglia and the development of spongiform change in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol (1998) 0.99
Involvement of capsaicin-sensitive neurones in hyperalgesia and enhanced opioid antinociception in inflammation. Naunyn Schmiedebergs Arch Pharmacol (1990) 0.98
Measurement of the inclusive jet cross section in pp collisions at √s = 7 TeV. Phys Rev Lett (2011) 0.98
Stimulation of hypothalamic beta-endorphin and dynorphin release by corticotropin-releasing factor (in vitro). Brain Res (1986) 0.98
Muscarinic inhibition of potassium-induced noradrenaline release and its dependence on the calcium concentration. Naunyn Schmiedebergs Arch Pharmacol (1975) 0.98
Enkephalin-induced inhibition of cortical neurones and the lack of this effect in morphine tolerant/dependent rats. Brain Res (1976) 0.98
Search for neutral minimal supersymmetric standard model Higgs bosons decaying to tau pairs in pp collisions at √s=7 TeV. Phys Rev Lett (2011) 0.97
Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists. Psychopharmacology (Berl) (1991) 0.97
Quality indicators for the prevention of type 2 diabetes in Europe--IMAGE. Horm Metab Res (2010) 0.97
Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography. J Pharmacol Exp Ther (1988) 0.97
Specificity of opioids towards the mu-, delta- and epsilon-opiate receptors. Neurosci Lett (1979) 0.97
Demonstration and characterization of alpha-human atrial natriuretic factor in human plasma. FEBS Lett (1985) 0.97
Prion protein mutation in family first reported by Gerstmann, Sträussler, and Scheinker. Lancet (1991) 0.97
GTPase and adenylate cyclase desensitize at different rates in NG108-15 cells. Mol Pharmacol (1987) 0.96
Motivational properties of opioids: evidence that an activation of delta-receptors mediates reinforcement processes. Brain Res (1987) 0.96
[TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy]. Med Klin (Munich) (1995) 0.96
Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res (1990) 0.95
Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists. Eur J Pharmacol (1988) 0.95